Literature DB >> 16985270

Hybrid scatter correction applied to quantitative holmium-166 SPECT.

Tim C de Wit1, Jianbin Xiao, J Frank W Nijsen, Fred D van het Schip, Steven G Staelens, Peter P van Rijk, Freek J Beekman.   

Abstract

Ho-166 is a combined beta-gamma emitter of which the betas can be used therapeutically. From the 81 keV gammas of Ho-166, SPECT images can be obtained, which give opportunities to guide Ho-166 therapy. Accurate reconstruction of Ho-166 images is currently hampered by photopeak-scatter in the patient, down-scatter in the detector, collimator and patient caused by the 1.4 MeV photons and by bremsstrahlung. We developed and validated a method for quantitative SPECT of Ho-166 that involves correction for both types of scatter plus non-uniform attenuation correction using attenuation maps. Photopeak-scatter (S) is compensated for by a rapid 3D Monte Carlo (MC) method that is incorporated in ordered subset (OS) reconstruction of the emission data, together with simultaneous correction for attenuation (A) and detector response (D); this method is referred to as OS-ADS. Additionally, for correction of down-scatter, we use a 14 keV wide energy window centred at 118 keV (OS-ADSS). Due to a limited number of available energy windows, the same 118 keV energy window was used for down-scatter correction of the simultaneously acquired Gd-153 transmission data. Validations were performed using physical phantom experiments carried out on a dual-head SPECT system; Gd-153 transmission line sources were used for acquiring attenuation maps. For quantitative comparison of OS-ADS and OS-ADSS, bottles filled with Ho-166 were placed in both a cylindrical phantom and an anthropomorphic thorax phantom. Both OS-ADS and OS-ADSS were compared with an ordered subset reconstruction without any scatter correction (OS-AD). Underestimations of about 20% in the attenuation map were reduced to a few per cent after down-scatter correction. The average deviation from the true activity contained in the bottles was +72% with OS-AD. Using OS-ADS, this average overestimation was reduced to +28% and with OS-ADSS the deviation was further reduced to 16%. With OS-AD and OS-ADS, these numbers were more sensitive to the choice of volumes of interest than with OS-ADSS. For the reconstructed activity distributions, erroneous background activity found with OS-AD was reduced by a factor of approximately 2 by applying OS-ADS and reduced by a factor of approximately 4 by applying OS-ADSS. The combined attenuation, photopeak-scatter and down-scatter correction framework proposed here greatly enhanced the quantitative accuracy of Ho-166 imaging, which is of the uppermost importance for image-guided therapies. It is expected that the method, with adapted window settings, also can be applied to other isotopes with high energy peaks that contaminate the photopeak data, such as I-131 or In-111.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16985270     DOI: 10.1088/0031-9155/51/19/004

Source DB:  PubMed          Journal:  Phys Med Biol        ISSN: 0031-9155            Impact factor:   3.609


  18 in total

1.  (⁹⁹m)Tc-MAA overestimates the absorbed dose to the lungs in radioembolization: a quantitative evaluation in patients treated with ¹⁶⁶Ho-microspheres.

Authors:  Mattijs Elschot; Johannes F W Nijsen; Marnix G E H Lam; Maarten L J Smits; Jip F Prince; Max A Viergever; Maurice A A J van den Bosch; Bernard A Zonnenberg; Hugo W A M de Jong
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-05-13       Impact factor: 9.236

2.  MIRD pamphlet No. 23: quantitative SPECT for patient-specific 3-dimensional dosimetry in internal radionuclide therapy.

Authors:  Yuni K Dewaraja; Eric C Frey; George Sgouros; A Bertrand Brill; Peter Roberson; Pat B Zanzonico; Michael Ljungberg
Journal:  J Nucl Med       Date:  2012-06-28       Impact factor: 10.057

3.  Absolute quantitative total-body small-animal SPECT with focusing pinholes.

Authors:  Chao Wu; Frans van der Have; Brendan Vastenhouw; Rudi A J O Dierckx; Anne M J Paans; Freek J Beekman
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-06-25       Impact factor: 9.236

4.  X-ray scatter correction for dedicated cone beam breast CT using a forward-projection model.

Authors:  Linxi Shi; Srinivasan Vedantham; Andrew Karellas; Lei Zhu
Journal:  Med Phys       Date:  2017-04-25       Impact factor: 4.071

5.  Holmium-166 radioembolization for the treatment of patients with liver metastases: design of the phase I HEPAR trial.

Authors:  Maarten L J Smits; Johannes F W Nijsen; Maurice A A J van den Bosch; Marnix G E H Lam; Maarten A D Vente; Julia E Huijbregts; Alfred D van het Schip; Mattijs Elschot; Wouter Bult; Hugo W A M de Jong; Pieter C W Meulenhoff; Bernard A Zonnenberg
Journal:  J Exp Clin Cancer Res       Date:  2010-06-15

6.  Neutron activation of holmium poly(L-lactic acid) microspheres for hepatic arterial radio-embolization: a validation study.

Authors:  M A D Vente; J F W Nijsen; R de Roos; M J van Steenbergen; C N J Kaaijk; M J J Koster-Ammerlaan; P F A de Leege; W E Hennink; A D van Het Schip; G C Krijger
Journal:  Biomed Microdevices       Date:  2009-08       Impact factor: 2.838

7.  MRI-based biodistribution assessment of holmium-166 poly(L-lactic acid) microspheres after radioembolisation.

Authors:  Gerrit H van de Maat; Peter R Seevinck; Mattijs Elschot; Maarten L J Smits; Hendrik de Leeuw; Alfred D van Het Schip; Maarten A D Vente; Bernard A Zonnenberg; Hugo W A M de Jong; Marnix G E H Lam; Max A Viergever; Maurice A A J van den Bosch; Johannes F W Nijsen; Chris J G Bakker
Journal:  Eur Radiol       Date:  2012-09-27       Impact factor: 5.315

8.  Holmium nanoparticles: preparation and in vitro characterization of a new device for radioablation of solid malignancies.

Authors:  Wouter Bult; Rosanne Varkevisser; Fouad Soulimani; Peter R Seevinck; Hendrik de Leeuw; Chris J G Bakker; Peter R Luijten; Alfred D van Het Schip; Wim E Hennink; J Frank W Nijsen
Journal:  Pharm Res       Date:  2010-07-31       Impact factor: 4.200

9.  Holmium-166 poly(L-lactic acid) microsphere radioembolisation of the liver: technical aspects studied in a large animal model.

Authors:  M A D Vente; T C de Wit; M A A J van den Bosch; W Bult; P R Seevinck; B A Zonnenberg; H W A M de Jong; G C Krijger; C J G Bakker; A D van het Schip; J F W Nijsen
Journal:  Eur Radiol       Date:  2009-09-30       Impact factor: 5.315

10.  Intratumoral administration of holmium-166 acetylacetonate microspheres: antitumor efficacy and feasibility of multimodality imaging in renal cancer.

Authors:  Wouter Bult; Stephanie G C Kroeze; Mattijs Elschot; Peter R Seevinck; Freek J Beekman; Hugo W A M de Jong; Donald R A Uges; Jos G W Kosterink; Peter R Luijten; Wim E Hennink; Alfred D van het Schip; J L H Ruud Bosch; J Frank W Nijsen; Judith J M Jans
Journal:  PLoS One       Date:  2013-01-08       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.